Please login to the form below

Not currently logged in
Email:
Password:

CDK4/6 inhibitor

This page shows the latest CDK4/6 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Verzenio scores a win in early-stage breast cancer

Lilly’s Verzenio scores a win in early-stage breast cancer

The two-year distant relapse-free survival rate was 93.6% in the Verzenio arm compared to 90.3% in the control arm. ... The positive results for Verzenio in the early breast cancer setting will be a blow for Pfizer’s rival CDK4/6 inhibitor Ibrance

Latest news

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

3 reasons why clinical trials will thrive in 2021
It’s not often that a single event can change the trajectory of an entire system, yet that is exactly what has happened to healthcare systems across the world and clinical...
#DemandDiversity: New research on COVID-19 clinical trial perceptions within minorities and high-risk populations
Lack of diversity in clinical trials still remains on of the biggest issues for COVID-19 clinical trials. But despite the growing discussions, calls for change, growing regulatory guidance and much...
Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...

Infographics